CTOs on the Move

Functional Pathways

www.fprehab.com

 
Functional Pathways is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Knoxville, TN. To find more information about Functional Pathways, please visit www.fprehab.com
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Southwest General Health Center

Southwest General Health Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cleveland, OH. To find more information about Southwest General Health Center, please visit www.swgeneral.com

Raydian Properties

Raydian Properties is passionate about creating a better Elder Living experience — the kind we want for our families. We are proud to be NJ’s largest provider of small group home dementia and Alzheimer’s care. We believe there is life beyond a diagnosis and with the right team, our residents can continue having a meaningful journey of a life worth living. Our homes welcome the flow of life with open kitchen, dining, and living spaces. Everyone who works at Raydian Properties is a Care Partner. We believe fresh, wholesome food nourishes both the mind and body. Care Partners prepare all food on-site and we believe in empowering every Care Partner to create joyful living experiences.

MiMedx Group, Inc

MiMedx Group, Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

CareCentrix

CareCentrix manages home nursing, infusion and medical equipment services for more than 20 million people across the country through a network of 5,000 credentialed home care providers.

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.